Hirudin Diabetic-Nephropathy Mechanistic Review
Mechanistic review of hirudin's anti-coagulant, anti-fibrotic, anti-thrombotic, anti-inflammatory effects in diabetic-nephropathy preclinical + clinical research — Tian 2024.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Mechanistic review of hirudin's anti-coagulant, anti-fibrotic, anti-thrombotic, anti-inflammatory effects in diabetic-nephropathy preclinical + clinical research — Tian 2024.
- Evidence level
- Expert consensus
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Mechanistic review evidence does NOT establish efficacy. Diabetic nephropathy is NOT an FDA-cleared indication for any hirudin-class agent; clinical use is investigational and primarily seen in TCM-integrated practice.
Molecular Profile
- Category
- Other
- Evidence tier
- Preclinical
- Source species
- Hirudo medicinalis (hirudin)
- Discovered
- 2024 · Tian F et al.
Biological Targets
- → thrombin; renal tubulointerstitial fibrosis; inflammatory cytokines; renal microthrombosis
Key Citations
- Tian F et al. (2024), Front Endocrinol (Lausanne) · PMID 38344666
External Resources
Related Other Compounds
Granulin (leech-derived)
Growth factor and wound-healing modulator — promotes angiogenesis and tissue regeneration.
Leech VEGF Modulator
Vascular endothelial growth factor pathway modulator — angiogenic and wound-healing implications.
Leech PDGF Modulator
Platelet-derived growth factor pathway modulator — implications for wound-healing.
Leech Granulin-A
Granulin-family peptide identified in Hirudo medicinalis — putative growth-factor / wound-healing analog (mechanistic only).